Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic impact of second-line treatment with nivolumab, pembrolizumab, and atezolizumab with and without the use of PD-L1 testing for patient selection.

中文翻译：

---

PD-L1测试对免疫检查点抑制剂对NSCLC二线治疗的成本效益和经济影响的影响

与肺癌的化疗相比，免疫检查点抑制剂可改善结局。肿瘤PD-L1受体表达正在研究中作为预测性生物标志物。这项研究的目的是评估在使用和不使用PD-L1测试进行患者选择的情况下，用nivolumab，pembrolizumab和atezolizumab进行二线治疗的成本效益和经济影响。